{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981469729765248.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.vaccine.2019.04.074"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0264410X19305626?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0264410X19305626?httpAccept=text/plain"}}],"dc:title":[{"@value":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981469729765255","@type":"Researcher","foaf:name":[{"@value":"Robert A. Feldman"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765261","@type":"Researcher","foaf:name":[{"@value":"Rainard Fuhr"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765250","@type":"Researcher","foaf:name":[{"@value":"Igor Smolenov"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765256","@type":"Researcher","foaf:name":[{"@value":"Amilcar (Mick) Ribeiro"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765257","@type":"Researcher","foaf:name":[{"@value":"Lori Panther"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765248","@type":"Researcher","foaf:name":[{"@value":"Mike Watson"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765253","@type":"Researcher","foaf:name":[{"@value":"Joseph J. Senn"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765252","@type":"Researcher","foaf:name":[{"@value":"Mike Smith"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765258","@type":"Researcher","foaf:name":[{"@value":"Ӧrn Almarsson"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765249","@type":"Researcher","foaf:name":[{"@value":"Hari S. Pujar"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765251","@type":"Researcher","foaf:name":[{"@value":"Michael E. Laska"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765259","@type":"Researcher","foaf:name":[{"@value":"James Thompson"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765254","@type":"Researcher","foaf:name":[{"@value":"Tal Zaks"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981469729765260","@type":"Researcher","foaf:name":[{"@value":"Giuseppe Ciaramella"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0264410X"}],"prism:publicationName":[{"@value":"Vaccine"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2019-05","prism:volume":"37","prism:number":"25","prism:startingPage":"3326","prism:endingPage":"3334"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://creativecommons.org/licenses/by-nc-nd/4.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0264410X19305626?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0264410X19305626?httpAccept=text/plain"}],"createdAt":"2019-05-09","modifiedAt":"2025-10-02","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360009142741626624","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017287048767616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Multifunctional polymeric micelle-based nucleic acid delivery: Current advances and future perspectives"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298757423240704","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Immunological imprint on peripheral blood in kidney transplant recipients after two doses of SARS-CoV-2 mRNA vaccination in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580229797136896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Emerging mRNA technologies: delivery strategies and biomedical applications"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232177337216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Current Vaccine Platforms in Enhancing T-Cell Response"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584341840480512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Comprehensive Evaluation of Lipid Nanoparticles and Polyplex Nanomicelles for Muscle-Targeted mRNA Delivery"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593800852736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Selecting and Using the Appropriate Influenza Vaccine for Each Individual"}]},{"@id":"https://cir.nii.ac.jp/crid/1390293865788946816","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lipid nanoparticles for mRNA delivery"},{"@language":"ja","@value":"脂質ナノ粒子を基盤とするmRNA送達システムの動向"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.vaccine.2019.04.074"},{"@type":"CROSSREF","@value":"10.1016/j.vaccine.2020.11.054_references_DOI_TXYkXQd8d3l8i2pMki617Ex7FgJ"},{"@type":"CROSSREF","@value":"10.2745/dds.37.237_references_DOI_TXYkXQd8d3l8i2pMki617Ex7FgJ"},{"@type":"CROSSREF","@value":"10.1016/j.apmt.2021.101217_references_DOI_TXYkXQd8d3l8i2pMki617Ex7FgJ"},{"@type":"CROSSREF","@value":"10.3389/fmed.2022.999374_references_DOI_TXYkXQd8d3l8i2pMki617Ex7FgJ"},{"@type":"CROSSREF","@value":"10.1039/d1cs00617g_references_DOI_TXYkXQd8d3l8i2pMki617Ex7FgJ"},{"@type":"CROSSREF","@value":"10.3390/vaccines10081367_references_DOI_TXYkXQd8d3l8i2pMki617Ex7FgJ"},{"@type":"CROSSREF","@value":"10.3390/pharmaceutics15092291_references_DOI_TXYkXQd8d3l8i2pMki617Ex7FgJ"},{"@type":"CROSSREF","@value":"10.3390/v13060971_references_DOI_TXYkXQd8d3l8i2pMki617Ex7FgJ"}]}